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ABSTRACT
Protein–protein interactions regulate many essen-
tial enzymatic processes in the cell. Somatic muta-
tions outside of an enzyme active site can there-
fore impact cellular function by disruption of criti-
cal protein–protein interactions. In our investigation
of the cellular impact of the T304I cancer mutation
of DNA Polymerase  (Pol), we find that muta-
tion of this surface threonine residue impacts crit-
ical Pol protein–protein interactions. We show that
proteasome-mediated degradation of Pol is reg-
ulated by both ubiquitin-dependent and ubiquitin-
independent processes via unique protein–protein
interactions. The ubiquitin-independent proteasome
pathway regulates the stability of Pol in the cytosol
via interaction between Pol and NAD(P)H quinone
dehydrogenase 1 (NQO1) in an NADH-dependent
manner. Conversely, the interaction of Pol with the
scaffold protein X-ray repair cross complementing 1
(XRCC1) plays a role in the localization of Pol to
the nuclear compartment and regulates the stability
of Pol via a ubiquitin-dependent pathway. Further,
we find that oxidative stress promotes the dissoci-
ation of the Pol/NQO1 complex, enhancing the in-
teraction of Pol with XRCC1. Our results reveal that
somatic mutations such as T304I in Pol impact criti-
cal protein–protein interactions, altering the stability
and sub-cellular localization of Pol and providing
mechanistic insight into how key protein–protein in-
teractions regulate cellular responses to stress.
INTRODUCTION
The vital importance of genome maintenance is under-
scored by the evolution of multiple DNA repair mecha-
nisms, each of which functions on a specific type or class
of damaged DNA. Of these, the base excision repair (BER)
pathway plays a critical role in repairing base damage and
DNA single-strand breaks that emerge from both endoge-
nous and exogenous sources. Failure to repair such DNA
lesions can lead to accumulation of DNA mutations and
chromosome alterations. As such, defects in DNA repair
pathways or proteins can predispose to cancer and disease
onset (1). Such defects in DNA repair can arise from mu-
tations in essential active site amino acid residues (2), as
well as those critical for post-translational modifications
(3), protein–protein interactions (4) or protein complex as-
sembly or dis-assembly (5). This study focuses on somatic
mutations found in the gene for DNA polymerase  (Pol)
and its impact on the BER pathway.
The BER pathway plays a major role in the repair of en-
dogenous and exogenous DNA damage that induces alky-
lated bases, oxidatively modified bases, base deamination
and DNA hydrolysis (6). Pol is the primary DNA poly-
merase involved in BER and both its 5′deoxyribose phos-
phate (5′dRP) lyase and nucleotidyl transferase activities
are important for BER (7,8). Mutations in Pol are found
in many human cancers and recently, as many as 75% of
the tumors analyzed in a colon cancer cohort were found
to bear mutations in the coding region or the UTR region
of the POLB gene (9–11). Modification of key amino acid
residues impacting the 5′dRP lyase and nucleotidyl trans-
ferase functions of Pol impairs BER efficiency and re-
sults in increased sensitivity tomanyDNAdamaging agents
(7,8). In addition, mutations that alter the structure of Pol
can affect its activity (12,13), such as the R137Q variant
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that confers cell sensitivity to the alkylating agent methyl
methanesulfonate (14) or the P242R mutant that predis-
poses the cell to genomic instability and transformation
(15).
Pol is critical for both the gap-tailoring and gap-filling
functions of BER (7,8,16). Pol is a bi-functional, two-
domain, 39 kDa enzyme (17). The N-terminal 8-kDa do-
main of Pol possesses 5′dRP lyase activity that removes
the sugar-phosphate lesion (5′dRP) during BER. The 31-
kDa polymerase domain of Pol is responsible for gap-
filling DNA synthesis during BER and resides within the C-
terminus (17). As we and others have described, these repair
functions of Pol are promoted or enhanced via essential
protein–protein interactions (18,19) as part of the suggested
hand-off or baton mechanism of BER (20). Of these pro-
tein partners, Pol interacts with X-ray repair cross com-
plementing 1 (XRCC1) (21,22), flap endonuclease 1 (FEN1)
(23,24), apurinic/apyrimidinic (AP) endonuclease 1 (APE1)
(25), proliferating cell nuclear antigen (PCNA) (26) and p53
(27), among others. Many somatic mutations of Pol have
been identified (9), including those that may prevent critical
protein–protein interactions, such as the R137Q mutation
that disrupts the interaction of Pol with PCNA (14).
Numerous studies have suggested that cellular homeosta-
sis of Pol protein levels is important for proper cellular
function and genome maintenance. Low levels of Pol in-
crease cancer susceptibility (28,29), while overexpression of
Pol is associated with increased carcinogenesis (30–32). As
such, protein degradation plays a central role in regulating
many processes of DNA repair and the cellular response
to DNA damage (33,34). As we have shown, part of the
homeostatic regulation of the Pol protein is mediated by
its interaction with XRCC1, since ‘free’ Pol (not bound to
XRCC1) can be targeted for ubiquitylation and degrada-
tion (18). In other unrelated studies, it has been found that
protein homeostasis can also be regulated by the core 20S
proteasome, by a process that does not require ubiquityla-
tion (35).
We have extended our studies on the homeostasis of Pol
to include cancer mutants that may trigger defects in key
protein–protein interactions. In this report, we have focused
on the T304I colon cancer mutation of Pol (11). This mu-
tation is located within the XRCC1 interaction domain,
known as the V303 loop (21,36,37), and we show here that
the Pol(T304I) mutant is defective in its ability to form
a heterodimer with XRCC1. Importantly, we find that the
Pol(T304I) protein is unstable, leading to enhanced degra-
dation. We also show that proteasome-mediated degra-
dation of Pol is regulated by both ubiquitin-dependent
and ubiquitin-independent processes via unique protein–
protein interactions. The ubiquitin-independent protea-
some pathway regulates the stability of Pol in the cytosol,
via an interaction between Pol andNAD(P)H quinone de-
hydrogenase 1 (NQO1) in an NADH-dependent manner.
Conversely, the interaction of Pol with XRCC1 plays a
role in the chromatin localization of Pol and regulates the
stability of Pol via a ubiquitin-dependent pathway. Fur-
ther, we find that oxidative stress promotes the dissociation
of the Pol/NQO1 complex, enhancing the interaction of
Pol with XRCC1. Our results reveal that somatic muta-
tions such as T304I in Pol mitigate protein–protein inter-
actions, thereby regulating the stability and sub-cellular lo-
cation of Pol. Herein, we provide mechanistic insight into
how key protein–protein interactions regulate cellular re-
sponses to stress.
MATERIALS AND METHODS
Materials
Heat-inactivated fetal bovine serum (FBS), ge-
neticin, Precast 4–20% Tris-glycine gels, L-glutamine,
antibiotic/antimycotic and penicillin/streptomycin were
from Thermo Fisher Scientific (Waltham, MA). Talon
metal affinity resin and puromycin were from Clontech
Laboratories (Takara Bio USA, Inc.). Gentamycin, N-
Ethylmaleimide (prepared as a 0.4 M stock solution in
ethanol), Anti-Flag M2 affinity gel, cycloheximide (pre-
pared as a 100 mM stock solution in DMSO), MG132
(prepared as a 100 mM stock solution in DMSO) and
hydrogen peroxide solution (diluted in H2O) were from
MilliporeSigma. McCoy’s 5A medium, Dulbecco’s mod-
ified Eagle’s medium (DMEM), -MEM and minimal
essential medium (MEM), as well as the Glutathione
agarose, Pierce IP lysis buffer and RIPA buffer, were from
Thermo Fisher Scientific. Dimethyl sulfoxide (DMSO)
was from Fisher Biotech (Fair lawn, NJ). Fugene 6 trans-
fection reagent and protease inhibitor cocktail tablets
were from Roche (Indianapolis, IN). NADH was from
Alfa Aesar Chemicals of Thermo Scientific (Tewksbury,
MA). Mono-S 5/50 GL column, Superdex 200 increase
10 × 300 GL column and glutathione sepharose 4B were
from GE Healthcare (Piscataway, NJ). All of the primers
were synthesized and purified by Thermo Fisher Scientific
(Waltham, MA).
Lentiviral vectors for expression of EGFP, Pol(WT) and
Pol mutants
Human Flag-tagged wild-type Pol cDNA, Flag-
Pol(WT), was cloned into the pENTR/D-TOPO plasmid
to create the pENTR/Flag-Pol(WT) vector as described
previously (38). Using this plasmid, K206A, K244A and
T304I mutations were made with the QuickChange XL
Site-Directed Mutagenesis kit. The primers used are
listed in Supplementary Table S1. Once sequence veri-
fied, the open reading frames from each vector and of
pENTR/EGFP were transferred into a Gateway-modified
lentiviral vector (either pLVX-IRES-Puro, pLVX-IRES-
Neo or pLVX-IRES-Hygro) by LR recombination, as we
have described previously (39). All the vectors developed
and used in this study are listed in Supplementary Table
S2.
Construction of the pGEX4T3 plasmids expressing GST fu-
sion proteins in Escherichia coli
To express and purify recombinant proteins (NQO1,
NQO1(Y128F), Pol(WT) and Pol mutants including
K206A/K244A (DM), T304I, K206A/K244A/T304I,
K72A, D256A, L301R/V303R/V306R (TM) and
TM/DM), the E. coli expression plasmid pGEX-4T-3
was modified to encode each of the open reading frames
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listed and then sequence validated. To construct pGEX-
4T-3 plasmids expressing the indicated proteins, primers
with SalI and NotI restriction enzyme sites were designed
and used for polymerase chain reaction (PCR) to amplify
the cDNA of the corresponding proteins. The sequence
of each PCR primer used is listed in Supplementary
Table S1. Both the PCR product(s) and the pGEX-4T-3
plasmid were digested by SalI and NotI, and the fragments
were purified by gel purification with the QiaQuick Gel
Extraction kit (Qiagen). The fragments were ligated and
transformed into BL21-CodonPlus-RP cells. The positive
plasmids were then isolated and sent to Eurofins Genomics
for sequence validation. The primers for sequencing are
listed in Supplementary Table S1. The plasmids with the
correct sequence were then used for protein expression
and purification. The expression of the proteins in E.
coli was then examined by Coomassie blue staining and
immunoblot analysis (Supplementary Figure S1A).
Cell culture and cell line development
HCT116 cells were cultured in McCoy’s media supple-
mented with 10% heat-inactivated FBS and Pen/Strep.
LN428 cells were cultured in -MEM supplemented
with heat-inactivated FBS (10%), gentamycin (5 g/ml),
pen/strep/amphotericin and L-glutamine (2 mM).
U2OS cells were cultured in DMEM supplemented
with heat-inactivated FBS (5%) and Penn/Strep. T98G
cells were cultured in MEM supplemented with heat-
inactivated FBS (10%), gentamycin (5 g/ml), penicillin
(80 units/ml), streptomycin (80 g/ml), amphotericin (32
g/ml), sodium pyruvate (1 mM) and non-essential
amino acids (0.1 mM). In most cases, cells trans-
duced with an EGFP-expressing lentivirus were used
as control. HCT116 cells, HCT116/Pol-KO cells,
LN428 cells and LN428/Pol-KO cells expressing Flag-
Pol(WT) and Flag-Pol mutants (including TM, K206A,
K244A, K206A/K244A, TM/K206A/K244A, T304I,
K244A/T304I and K206A/K244A/T304I) were developed
by lentiviral transduction. The generation of lentiviral
particles and the collection and isolation of lentiviral
particles were performed as described previously (18,38).
Stable cell lines were cultured in selection media for 1 week.
Whole cell lysates (WCL) were prepared and analyzed by
immunoblotting to determine the expression of the desired
proteins. All of the cells were cultured at 5% CO2 and 37◦C.
All the cell lines developed and used in this study and their
growth media are listed in Supplementary Table S3.
Purification of recombinant proteins expressed in E. coli
For the binding assay (Open-SPR), the Pol/NQO1
interaction in vitro assay and 20S proteasome in vitro
degradation assay, we purified Pol(WT), Pol(T304I),
NTD-XRCC1(1-151)-His, NQO1 and NQO1(Y128F)
proteins. The protein purification scheme is shown in
Supplementary Figure S1D. The procedure was per-
formed as described previously (40,41) with some minor
modifications as described: BL21-CodonPlus-RP cells
expressing GST-Pol(WT), GST-Pol(T304I), GST-
NQO1 and GST-NQO1(Y128F) were utilized for GST-tag
protein expression. An overnight culture was added to
fresh LB medium with 1:100 dilution. The cells were
cultured until OD600 reached 0.6–1, then 0.4 mM iso-
propyl -D-1-thiogalactopyranoside (IPTG) was added
and cells were cultured overnight at 18◦C. The cell pellet
was collected by centrifugation at 5000 rpm for 10 min
at 4◦C. The cell pellet was then washed with lysis buffer
(50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) pH 7.4, 500 mM NaCl, 1× Sigma protease
inhibitor cocktail, 1 mM Dithiothreitol (DTT) and 1 mM
EDTA). Cells were resuspended in lysis buffer and lysed by
sonication (10 s on and 20 s off for 2 min). Cell lysates were
then centrifuged at 10 000 rpm for 20 min at 4◦C twice to
collect the cell lysate supernatant. Cell lysate supernatant
was mixed with 2 ml of glutathione sepharose 4B resin,
washed with lysis buffer and the mixture was rotated
overnight. The resin was washed with lysis buffer four
times. Then, the resin was washed with 50 mMHEPES pH
7.4, 100 mM NaCl (buffer A) to exchange into a low salt
buffer. To remove the GST-tag, the resin was resuspended
with Buffer A and 0.5 ml of 1 mg/ml GST-TEV protease
and incubated overnight at 4◦C with rotation. The resin
was poured into a column and the flow-through was
collected. The column was washed again with Buffer A and
the flow-through was collected.
For Pol and its mutants, the flow-through was loaded
onto a Mono-S column equilibrated with 10 column vol-
umes of buffer A at a flow rate of 1 ml/min. The Mono-S
column was washed with 10 ml Buffer A at a flow rate of
1 ml/min, then the Pol protein was eluted with 0–100%
Buffer B (50 mM HEPES pH 7.4, 1 M NaCl) 30 min and
100% Buffer B for another 20 min. The fractions contain-
ing Polwere pooled and concentrated withMillipore Ami-
conUltra-4 centrifuge filters. The concentrated fractionwas
loaded onto a gel filtration column (Superdex 200 increase
10/300 GL, GEHealth) equilibrated in 50 mMHEPES pH
7.4, 150 mMNaCl. After the proteins were eluted, fractions
were collected and concentrated. Purity was examined by
sodium dodecylsulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) followed by Coomassie blue staining and
immunoblot, as shown in Supplementary Figures S1F and
S3F.
For NQO1 and NQO1(Y128F), the flow-though was
concentrated with Millipore Amicon Ultra-4 centrifuge fil-
ters. The concentrated flow-through was loaded onto a
gel filtration column. The procedure was performed as de-
scribed for the purification of Pol and its mutants above.
To purify NTD-XRCC1(1-151)-His, the plasmid
pET21a-NTD-hXRCC1(1-151)-His was transformed into
BL21 cells. The expression of the protein was induced by
the addition of 1 mM IPTG. The His-tagged XRCC1 pro-
tein was purified by Talon Metal affinity resin (Clontech).
The eluent containing the His-Tagged XRCC1 protein was
further purified by gel filtration, as described above. The
purification processes are summarized in Supplementary
Figure S1D. Representative chromatographs are shown in
Supplementary Figure S1E.
Cell extract preparation. For newly developed stable cell
lines, the expression level of proteins was determined by im-
munoblot usingWCL.WCLwas prepared as described pre-
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viously and quantified using a DC protein assay following
the microplate protocol provided by the company with the
DC protein assay kit (Bio-Rad) (18).
Immunoprecipitation (IP). To study how the Pol(T304I)
mutation affects the interaction of XRCC1 with Pol and
how H2O2 treatment affects the Pol/XRCC1 interaction,
anti-Flag M2 affinity gel, Pol (Clone61) antibody and
XRCC1 antibodies were used to immunoprecipitate (IP)
Flag-Pol(WT) and Flag-Pol mutants, endogenous Pol
and XRCC1, respectively. The IP was performed as de-
scribed previously (18).
Immunoblot. Twenty to thirty micrograms of WCL or 5–
10l immunoprecipitated proteins were loaded on a pre-
cast 4–12% NuPAGE Tris-glycine gel, run for 2–3 h at
100–130 volts. The gel was transferred and the membrane
was blotted with primary antibodies, as indicated. The in-
formation for the primary antibodies used herein is listed
in Supplementary Table S4. After washing, Immun-Star
Goat anti-mouse-HRP conjugate (Bio-Rad) or Immun-
Star Goat anti-rabbit-HRP conjugate (Bio-Rad) secondary
antibody was used. The membrane was illuminated and the
bands were quantified using Image Lab (Bio-Rad).
Surface plasmon resonance (OpenSPR) assay
Binding experiments were carried out in anOpenSPR local-
ized surface plasmon resonance (LSPR) biosensor (Nicoya
Lifesciences). The running buffer used throughout the
experiment contains 25 mM HEPES pH 8.0, 150 mM
NaCl, 200 mM MgCl2, 0.1% Tween 20 and 1 mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP). Pol(WT)
or Pol(T304I)mutantwas diluted in immobilization buffer
(10mMmalate pH6.0) at a final concentration of 50g/ml.
The carboxyl sensor surface (Nicoya) was activated by in-
jecting a mixture of 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (42) and N-hydroxysuccinimide (NHS) followed
by immobilization of Pol(WT) or Pol(T304I) via cova-
lent coupling. The free carboxyl groups were deactivated us-
ing blocking buffer (Nicoya). After achieving a stable base-
line, the running buffer was injected for blank measurement
followed by successive injections of buffer matched XRCC1
at concentrations of 10, 100 nM, 1, 2, 5 and 10 M. The
data were analyzed using TraceDrawer 1.8 and KD values
were calculated using the affinity model where the equi-
librium dissociation constant, KD, is calculated from a re-
sponse versus concentration plot using non-linear regres-
sion (Y = Bmax * c / (c + KD)).
Stability assay for Pol(WT) and Pol mutants
The stability assay of Pol(WT) and the Pol mutant pro-
teins was carried out as described previously (18). The level
of Pol and mutants was determined by immunoblot, and
the intensity of bands was quantified using Image Lab (Bio-
Rad). To study the stability of Pol(WT), Pol(T304I) and
Pol(T304I/DM), cells were treated with 0.2 mM cyclohex-
imide (Cyc) or Cyc plus 25 MMG132 for 0, 2, 4 and 6 h.
WCL was prepared and the level of Pol(WT) or Pol mu-
tants was determined and quantified. The level of PCNA or
-tubulin was set as a loading control in these experiments.
Quantitative RT-PCR analysis
Expression of mRNA for Pol(WT) and Pol mutants
was measured by quantitative RT-PCR using an Applied
Biosystems StepOnePlus system (39). Briefly, 80 000 cells
were lysed and reverse transcribed using theAppliedBiosys-
tems Taqman® Gene Expression Cells-to-CT kit, as we
have described previously (43). Analysis of mRNA expres-
sion was performed as per the instruction of the manufac-
turer (CT method). Hs00160263 m1 (human Pol) was
used in the TaqMan Gene Expression Assay. Samples were
run in triplicate and the results shown are the mean± SD of
all three analyses. The mRNA level of Pol is then normal-
ized to the expression of human -actin (Hs99999903 m1).
Determination of ubiquitylated Pol in cells
HCT116 cells and LN428 cells expressing EGFP, Flag-
Pol(WT), Flag-Pol(T304I), Flag-Pol(K244A/T304I)
or Flag-Pol(T304I/DM) were used. Cells were transfected
with 12 g pCDNA-HA-ubiquitin with Promega Fugene
HD. The Flag-Pol and Flag-Pol mutants were IP with
M2 agarose, and the eluted IP products were probed with
anti-HA antibody and Pol(595) antibody to evaluate ubiq-
uitylated Pol (18).
In vitro assay to determine the interaction of Pol with
NQO1––cell lysates
BL21-CodonPlus-RP cells expressing GST-Pol and GST-
NQO1 were utilized for GST-tag protein purification. The
procedure describing the binding of the GST-tagged pro-
teins to glutathione-agarose (Thermo Fisher Scientific) is
described above (‘Purification of recombinant proteins ex-
pressed inE. coli ’). After the GST-tagged proteins (purified
from300ml culture) were bound to the glutathione-agarose,
the agarose/GST-tagged protein complex was washed with
lysis buffer (see above). The agarose was then aliquoted into
three fractions (1, 2 and 3), and each fraction was mixed
with 1 ml of cell lysate prepared from a 1 × 150 mm dish of
HCT116, LN428 or T98G cells, respectively. The mixture
was incubated at 4◦C overnight with rotation. The agarose
was then washed 3–5 times with lysis buffer. After washing,
each agarose preparation (1, 2 and 3) was separated into two
fractions (1a, 1b, 2a, 2b, 3a, 3b). One set of fractions (1a, 2a,
3a) was then used to determine the total proteins captured
by the glutathione-agarose/GST-protein complex. The sec-
ond set of fractions (1b, 2b, 3b) was then incubated with
GST-TEV protease overnight at 4◦C to release Pol and
its mutants, allowing analysis of the proteins bound only to
the glutathione-agarose/GST fragment. After the removal
of the buffer from the glutathione-agarose, 100 l of 2×
Laemmli buffer (62.5 mM Tris–HCl, pH 6.8, 20% (w/v)
glycerol, 2% SDS, 0.01% Bromophenol Blue) was added
to (i) the glutathione-agarose/GST-protein complex or (ii)
glutathione-agarose/GST fragment complex, followed by
incubation in boiling water for 5 min to elute the bound
proteins. The level of PARP1, XRCC1, TBP1 (26S protea-
some), C2 (20S proteasome) and NQO1 in the elution was
examined by immunoblot.
To study the effect of Pol mutants on the interaction of
Pol with NQO1, 100 ml of BL21-CodonPlus-RP cells ex-
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pressingGST-Pol, GST-Polmutants, GST-NQO1,GST-
NQO1(Y128F) orGST-EGFPwere used andGST-proteins
were isolated with glutathione-agarose. The glutathione-
agarose was incubated with cell lysates from HCT116 cells
for 4 h and the GST-tagged proteins were eluted with 2×
Laemmli buffer by heating in boiling water. The level of
bound PARP1, XRCC1, TBP1, C2, NQO1 and loaded
Pol and its mutants (GST) were examined by immunoblot.
GST-EGFP served as a negative control.
To study the effect of dicumarol treatment on the inter-
action of Pol with NQO1, 200 or 400 M dicumarol in
DMSO was used to treat HCT116, LN428, LN428/EGFP,
LN428/Flag-Pol, T98G and T98G/Flag-Pol cells for 5
h. Then, WCL was prepared and quantified and the level of
bound PARP1, XRCC1, Pol, p53, NQO1 and PCNA was
examined as above.
Determination of the interaction of Pol with
NQO1––purified proteins
Glutathione-agarose was used to bind GST-Pol(WT),
GST-Pol(T304I) and GST-Pol(TM). The glutathione-
agarose with the GST-tagged proteins was then incubated
with 1 g of purified NQO1 or NQO1(Y128F) in 1 ml of 50
mM HEPES pH 7.4 buffer with 150 mM NaCl, 20 g/ml
of bovine serum albumin (BSA) and 5 mM DTT overnight
at 4◦C. The agarose was washed with TBS five times. The
bound proteins were eluted with 30 l of 2× Laemmli sam-
ple buffer by boiling 5 min in water. The level of NQO1 and
Pol was examined by immunoblot.
In vitro Pol degradation assay mediated by the 20S protea-
some
Purified Pol(WT) and Pol(T304I) recombinant proteins
(200 ng each) were incubated with 500 ng of the 20S protea-
some (Sigma) in the absence or presence of 0.5% DMSO,
50 MMG132, 500 ng NQO1 or 500 ng NQO1 plus 5 mM
NADH in 10 l of reaction buffer (100 mM Tris–HCl pH
7.5, 150 mM NaCl, 5 mM MgCl2, 2 mM DTT, 20 g/ml
BSA, 10% glycerol) at 37◦C for 1 h. After 1 h, 10 l of 2×
Laemmli sample buffer was added and the samples were
boiled for 5 min in water. The level of the proteins Pol,
NQO1 and the 20S proteasome protein C2 was examined
by immunoblot.
XRCC1 and Pol knockout by CRISPR/Cas9 in U2OS,
T98G, HCT116 and LN428 cells
Guide RNAs (gRNAs) targeting XRCC1 exon 2 or exon 3
or targeting Pol exon 1 were designed using the CRISPR
Design Tool (44), and as described (45). The gRNAs for
XRCC1 were cloned into pLentiCRISPRv2 (a gift from
Feng Zhang) (46). The gRNAs for Pol were cloned into
pLentiGuide and pLentiCRISPR-GFP. The sequence of
each gRNA target sequence is listed in Supplementary
Table S1 and the plasmids are listed in Supplementary
Table S2. The experiment was performed as described
(46,47). Briefly, the U2OS, T98G, HCT116 and LN428
cell lines were transduced by lentivirus prepared from
the corresponding vectors (see Supplementary Table S2)
(18,48). Cells were selected by culturing in puromycin-
supplemented media (1 g/ml) for 5 days after transduc-
tion for 48 h. Cells were then seeded for selection of sin-
gle cell clones and knockout was confirmed by immunoblot.
The gene knockout was also confirmed by DNA sequenc-
ing of the targeted exon 2 or exon 3 (XRCC1) using primer
pairs XRCC1-KO-2-fw/XRCC1-KO-2-re or XRCC1-KO-
3-fw/XRCC1-KO-3-re, or by DNA sequencing of the tar-
geted exon 1 (Pol) with primers Pol-KO-1-Fw and Pol-
KO-1-Re, respectively. The sequence of the PCR primers
used to perform PCR and DNA sequence analysis is listed
in Supplementary Table S1.
NAD+/NADH measurements
The level of NAD+ and NADH in LN428 cells treated with
0, 150, 200 and 250 M H2O2 for 3 h was measured by
the Enzychrome NAD+/NADH assay kit (BioAssay Sys-
tems) as we have described previously (48). Briefly, LN428
cells were seeded in 6-well plates at a density of 2 × 105
cells per well. Twenty-four hours later, cells were treated
with the indicated concentration of H2O2 for 3 h. Follow-
ing treatments, cells were harvested and a suspension of 2
× 105 cells was divided in half for measuring NAD+ and
NADH, respectively. Cell pellets were homogenized using
plastic pestles and the extraction of NAD+ andNADHwas
performed as per the manufacturer’s protocol using the ly-
sis buffers provided. Extracts were heated at 60◦C for 5 min
and neutralized with the extraction buffer. Samples were
spun down and the supernatant was immediately used for
measurements of NAD+/NADH content using a Molec-
ular Devices VersaMax™ tune-able plate reader at 565 nm
wavelength.
Isolation of cytosolic, nucleoplasmic and chromatin fractions
To study the distribution of Pol in cells (LN428 express-
ing Flag-Pol(WT), Pol(T304I) or Pol(TM), as well as
U2OS, T98G and LN428 cells with or without XRCC1),
fractions of cytosolic, nucleoplasmic (soluble nuclear pro-
teins) and chromatin-bound proteins were isolated. Cy-
tosolic, nucleoplasmic and chromatin fraction isolation was
performed as follows: cells were cultured until the plates
reached 80–90% confluence (100 mm plates). Media was
removed and the cells were then washed twice with cold
phosphate-buffered saline, and 300 l of cytoplasmic lysis
buffer (10 mM Tris–HCl pH 8.0, 0.34 M Sucrose, 3 mM
CaCl2, 2 mMMg acetate, 0.1 mMEDTA, 0.5%Nonidet P-
40, protease inhibitor) was added to plates. Cells were then
scraped and the cell/buffer mixture was transferred to 2 ml
Eppendorf tubes. Cells were incubated for 15min on ice and
then were centrifuged for 10 min at 4000 rpm (4◦C). The su-
pernatant is the cytoplasmic fraction and was collected and
prepared for immunoblot.
The pellet (nuclei) was carefully washed with 300 l of
wash buffer (10 mM Tris–HCl pH 8.0, 0.34 M sucrose, 3
mM CaCl2, 2 mM Mg acetate, 0.1 mM EDTA, protease
inhibitor) and then the buffer was removed with a pipette
without resuspension or centrifugation. The nuclei were
lysed in 100 l nuclear lysis buffer (20 mMHEPES pH 8.0,
3 mMEDTA, 10% glycerol, 150 mM potassium acetate, 1.5
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mM MgCl2, 0.1% Nonidet P-40, protease inhibitor) and
incubated on ice for 30 min. The nuclear lysate was cen-
trifuged at 13 000 rpm for 10 min (4◦C). Here, the super-
natant is the nucleoplasmic fraction and was collected and
prepared for immunoblot.
The pellet (chromatin fraction) was washed with 300 l
nuclear lysis buffer and then with 750 l nuclease incuba-
tion buffer (150 mM HEPES pH 8.0, 10% glycerol, 50 mM
potassium acetate, 100 mM KCl, 1.5 mM MgCl2, protease
inhibitor) carefully with a pipette without resuspension or
centrifugation. The pellet was then re-suspended in 75 l of
nuclease incubation buffer with 1.5 l benzonase and incu-
bated for 15 min at 37◦C and mixed to re-suspend every 5
min. The resuspension was centrifuged at 13 000 rpm for 15
min (4◦C). Here, the supernatant is the chromatin fraction
and was collected and prepared for immunoblot.
The level of Pol, XRCC1, PARP1, NQO1 and -tubulin
in each of the fractions was determined by immunoblot.
The relative level of Pol in the cytosolic, nucleoplasmic
and chromatin fractions was quantified using Image Lab
(Bio-Rad). For LN428 cells expressing Flag-Pol(WT) and
Pol(T304I) or for U2OS, T98G and LN428 cells with
or without XRCC1, the relative level of Pol in each iso-
lated fraction was normalized to the corresponding cytoso-
lic fraction.
To evaluate how H2O2 treatment affects the location of
Pol, LN428 or T98G cells were treated with H2O2 (150
M) for 0, 2, 4, 6, 12 or 24 h and the cytosolic and chro-
matin fractions were isolated. The relative level of Pol,
XRCC1 and PARP1 was quantified using Image Lab (Bio-
Rad) and the ratio of Pol/PARP1 and XRCC1/PARP1
was calculated. To evaluate whether H2O2 treatment stimu-
lates the expression of Pol in LN428 or T98G cells, the
cells were treated with H2O2 (150 M) for 0, 2, 4, 6, 12
or 24 h and then WCL were prepared. The relative level of
Pol, XRCC1, PARP1 and -tubulin was examined by im-
munoblot. The level of Pol and -tubulin was quantified
using Image Lab (Bio-Rad) and the ratio of Pol/-tubulin
was calculated.
In vitro Pol degradation assay following dicumarol treat-
ment
Dicumarol was dissolved in DMSO. LN428, HCT116,
T98G, LN428/Flag-Pol(WT) and T98G/Flag-Pol(WT)
cells were treated with dicumarol (200 or 400 M) for 5 h.
Then, WCLs were prepared and the level of Pol, p53 (pos-
itive control), PARP1, XRCC1, NQO1 and PCNA was ex-
amined by immunoblot. The level of Pol was quantified
using Image Lab (Bio-Rad) and the relative level of Pol
was calculated as the ratio of Pol/PCNA.
Immunofluorescence (IF) assay
To determine whether H2O2 treatment promotes the nu-
clear translocation of Pol, 2× 105 LN428 cells were seeded
into 35 mm dishes with #1.5 cover glass bottoms (World
Precision Instruments, FD35-100) for 24 h. Cells were then
treated with H2O2 (150 M) for 24 h. Control and H2O2
treated cells were then fixed with 95% cold methanol for
15 min, permeabilized with 0.1% Triton X-100 for 15 min
and blocked with 2% bovine serum albumin for 45 min.
Cells were then incubated with mouse anti-Pol antibody
(Clone 61) at 1:100 dilution for 2 h. After washing, cells
were incubated with Alexa Fluor 488 conjugated goat anti-
mouse IgG (Life Technologies, Inc.) at 1:1000 dilution for
1 h. After washing, cells were mounted using Prolong Gold
anti-fade reagent with DAPI (Life Technologies, Inc.) and
a #1.5 coverslip. Cells were imaged with a Nikon A1r con-
focal microscope using a Plan Apo  60× objective (NA =
1.4). For each field, an image stack through theZ-plane was
collected to fully sample cells. Images were quantified us-
ing a custom macro written for NIS-Elements (Laboratory
Imaging). Briefly, a maximum intensity projection of each
image stack was generated, and the DAPI stain was used
to define each nucleus as a region of interest (ROI). ROIs
touching the image border were removed, and then mean
Pol intensity per nucleus was measured; 100–200 cells per
condition were analyzed. Statistical analysis was performed
using Student’s t-test.
To determine the relative distribution of Pol in the
nucleus and cytoplasm, U2OS/Cas9, U2OS/XRCC1-
KO.2.1, U2OS/XRCC1-KO.3.1, U2OS/Pol-KO.2.1,
T98G/Cas9, T98G/Pol-KO.2.2, T98G/XRCC1-KO.2.4
and T98G/XRCC1-KO.3.4 cells were seeded into cover
glass bottom dishes as above and cultured for 24 h. Cells
were fixed with 4% paraformaldehyde for 15 min, perme-
abilized with 0.1% Triton X-100 for 15 min and blocked
with 2% bovine serum albumin for 45 min. Cells were
then incubated with mouse anti-Pol antibody (Clone
61) at 1:100 dilution and rabbit anti-XRCC1 antibody at
1:500 dilution for 2 h. After washing, cells were incubated
with Alexa Fluor 488 conjugated goat anti-mouse IgG
and Alexa Fluor 568 conjugated goat anti-rabbit IgG at
1:1000 dilution, together with Alexa Fluor 647 conjugated
phalloidin at 1:40 dilution for 1 h (Life Technologies, Inc.).
After washing, cells were mounted using Prolong Gold
anti-fade reagent with DAPI (Life Technologies, Inc.) and
a #1.5 coverslip. Cells were imaged with a Nikon A1r
confocal microscope using a Plan Apo  60× objective
(NA = 1.4). For each field, an image stack through the
Z-plane was collected to fully sample cells. Cells were
quantified using a custom macro written for NIS-Elements
(Laboratory Imaging). Briefly, a maximum intensity pro-
jection of each image stack was generated, and the DAPI
and phalloidin stains were used to define the nuclear and
cytoplasmic components, respectively. For each image field,
mean Pol intensity for each compartment was measured
and exported, and used to determine nuclear/cytoplasmic
ratios and whole cell mean intensities (nuclear + cyto-
plasmic mean values). Nine image fields were analyzed,
yielding 100–200 cells per condition. Statistical analysis
was performed using one-way ANOVA followed by Tukey’s
multiple comparison test.
Statistical analysis
All data are shown as the mean ± standard deviation from
3 to 4 independent experiments. Student’s t-test was used
for comparisons between two groups. For multiple compar-
isons, one-way or two-way ANOVA was used, followed by
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either Tukey’s or Dunnett’s multiple comparison test. Sta-
tistical analysis was performed using GraphPad PRISM.
RESULTS
DNA polymerase  colon cancer mutant T304I disrupts
Pol/XRCC1 complex formation and promotes Pol ubiq-
uitylation and degradation
DNA polymerase  (Pol) and XRCC1 form a tight het-
erodimeric complex via an interaction between the C-
terminal domain of Pol and the N-terminal domain of
XRCC1 (21,36,37). Amino acid residues P300 to E309 on
Pol form the V303 loop, a domain that interfaces with
XRCC1 via a hydrophobic pocket spanning amino acid
residues F67 and V86 on XRCC1 (21,37). In our previous
report, we demonstrated that disrupting the Pol/XRCC1
heterodimer by mutating residues on Pol within this V303
loop impacts the stability of Pol, inducing its ubiquity-
lation and proteasome-mediated degradation (18). Several
studies have demonstrated a high percentage of Pol muta-
tions in cancer (49–51). More recently, Sweasy et al. found
as many as 75% of the tumors analyzed in a colon cancer
cohort bear mutations in the coding region or the UTR re-
gions of the POLB gene (11). One of these colon cancer
mutations is located within the V303 loop, the T304I mu-
tation, and is found in colon cancer tissue but not in the
corresponding normal tissue (11) (Figure 1A). The struc-
ture of the Pol/XRCC1 heterodimer (3LQC; the oxidized
form of XRCC1) shows that the water molecules (orange
spheres) form a network ofH-bond interactions in the vicin-
ity of residue T304, whereas the reduced XRCC1 structure
(3K75, left panel) does not have water molecules built into
the model owing to lower resolution of the structure. From
the location of the water molecules in the structure, it can
be surmised that mutation of T to I for residue 304 in Pol
may displace some of these H-bond interactions, suggesting
that the Pol(T304I) mutation may interfere with or even
disrupt water-mediated interactions at the interface with
XRCC1 (Figure 1A).
To determine whether the T304I mutation disrupts the
Pol/XRCC1 interaction in vivo and in vitro, we used
lentiviral transduction to modify the colon cancer cell line
HCT116, creating stable cell lines that express either Flag-
Pol(WT) or Flag-Pol(T304I). The expression of Flag-
Pol(WT) and Flag-Pol(T304I) had no effect on the level
of other BER-related proteins such as PARP1, XRCC1,
PCNA and HSP90 (Supplementary Figure S1B). Our ear-
lier studies revealed that Pol mutants unable to bind
XRCC1 are unstable and present with a lower basal pro-
tein level in human cells (18). Consistent with these findings,
the basal level of the Flag-Pol(T304I) protein is reduced as
compared to the Flag-Pol(WT) protein while the mRNA
level of Flag-Pol(T304I) and Flag-Pol(WT) are com-
parable (Supplementary Figure S1B and C). Analysis of
HCT116 cell lysates by immunoprecipitation/immunoblot
(IP/IB) using either the Flag-Ab (M2) or the XRCC1-
Ab confirms the strong heterodimer formation of Flag-
Pol(WT) protein with endogenous XRCC1, whereas the
T304I mutation of Pol disrupts the formation of the
Pol/XRCC1 complex (Figure 1B). To further confirm
that the Pol(T304I) mutation disrupts the Pol/XRCC1
interaction, we used an OpenSPR (surface plasmon res-
onance) assay to calculate the binding affinities of the
Pol(WT)/XRCC1 and Pol(T304I)/XRCC1 interactions.
The N-terminal fragment of XRCC1 [NTD-XRCC1(1-
151)-His] and theWT andmutant forms of Pol [Pol(WT)
and Pol(T304I)] were expressed in E. coli and puri-
fied (Supplementary Figure S1A and D–F). The Open-
SPR assay revealed that the binding affinity of Pol(WT)
to XRCC1 ranges from 2.38- to 12.48-fold higher than
Pol(T304I), as indicated by theKD values, with a meanKD
differential of 6.18 (Figure 1C and Supplementary Figure
S1G–H). This confirms that the Pol(T304I) mutation per-
turbs the Pol/XRCC1 interaction, consistent with an ear-
lier report showing purified His-tagged Pol(T304I) loses
its interaction with XRCC1 in vitro (52).
The stability of Pol depends on complex formation with
XRCC1 (18). We hypothesized that the low basal level of
Flag-Pol(T304I) in HCT116 cells is the result of ubiq-
uitylation and degradation via the proteasome pathway.
To avoid the potential interference of endogenous Pol in
HCT116 cells, we developed HCT116/Cas9 control and
HCT116/Pol-KO cells (Supplementary Figure S1B, mid-
dle panel). With these, we then expressed EGFP, Flag-
Pol(WT) or Flag-Pol(T304I) in the HCT116/Pol-KO
cells by lentiviral transduction (Supplementary Figure S1B,
bottom panel and Supplementary Tables S2, S3 and S5).
As shown, the Flag-Pol(WT) protein is more stable than
Flag-Pol(T304I) in the presence of the protein synthesis in-
hibitor cycloheximide (Cyc), while treatment with the pro-
teasome inhibitor MG132 stabilizes both Pol(WT) and
Pol(T304I) proteins (Figure 1D and Supplementary Fig-
ure S1I and J). The presence of endogenous Pol has no
effect on the stability of the expressed Flag-Pol(WT) and
Flag-Pol(T304I) proteins (Figure 1D and Supplementary
Figure S1I and J). Further, we find enhanced ubiquityla-
tion of Flag-Pol(T304I) when expressed in HCT116 cells,
as compared to the Flag-Pol(WT) protein (Figure 1E and
Supplementary Figure S1K).
Pol(T304I) stability is mediated by a ubiquitin-independent
proteasome pathway
Pol is ubiquitylated on two lysine residues, K206 and
K244, leading to proteasomal-mediated degradation (18).
When expressed in LN428 cells, modification of both ly-
sine residues to alanine (K206A/K244A, denoted as DM)
stabilizes both the WT isoform of Pol, Flag-Pol(WT),
as well as the separation-of-function mutant of Pol that
does not bind XRCC1 (L301R/V303R/V306R, denoted
as TM), Flag-Pol(TM), as we have reported (18). Simi-
larly, the DM mutations increase the basal level of Flag-
Pol(WT) and Flag-Pol(TM) protein when expressed in
HCT116 cells (Supplementary Figure S2A). However, the
K244A and DM mutations were found to decrease the
basal level of the Flag-Pol(T304I) protein in HCT116 and
LN428 cells (Figure 2A–C), whereas qRT-PCR analysis
shows that there is no significant difference in mRNA ex-
pression (Supplementary Figure S2B). This may suggest
that the T304I mutation alters the target site for ubiquityla-
tion. To that end, we evaluated whether Flag-Pol(T304I)
shows an elevated level of ubiquitylation and if the K244A
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Figure 1. The T304I cancer mutation of Pol disrupts the Pol/XRCC1 interaction and induces the ubiquitylation and degradation of Pol. (A)
Pol(T304I) location and the structure of Pol interacting with XRCC1 shown in the reduced (left) and oxidized (right) form. Left panel: Cyan: 2FMS;
Gray: XRCC1 in 3K75 (Pol bound to reduced XRCC1); Wheat: Pol in 3K75 (Pol bound to reduced XRCC1). Right panel: Cyan: 2FMS; Gray:
XRCC1 in 3lqc(Pol: oxidized XRCC1); Slate: Pol in 3K75(Pol: oxidized XRCC1); Orange spheres: Water molecules. (B) Pol(T304I) mutation dis-
rupts the Pol/XRCC1 interaction in HCT116 cells. Top panel: Flag (M2) immunoprecipitation (IP) followed by an XRCC1 immunoblot (IB) shows
that Pol(T304I) immunoprecipitates less XRCC1 than does Pol(WT). Bottom panel: XRCC1-IP followed by a Flag (M2) IB shows that XRCC1 im-
munoprecipitates less Pol(T304I) than Pol(WT). The level of PARP1 binding to XRCC1/Pol complex was also examined. The blots shown are an
analysis of lysates from HCT116 cells (10 l of IP eluates was loaded per lane). (C) Analysis of the interaction between Pol and XRCC1 by OpenSPR
shows that the Pol(T304I) mutation (right) decreases the binding affinity (2.38–12.48 fold; mean = 6.18) to XRCC1 as compared to Pol(WT) (left). The
complete set of raw data (sensograms) and the repeat experimental datasets are shown in Supplementary Figure S1G and H. (D) Pol(T304I) mutation
induces the degradation of Pol. Top panel: a representative immunoblot image of cycloheximide (Cyc) treatment resulting in the enhanced degradation
of Pol(T304I) in HCT116 cells (left panel). Treatment with the proteasome inhibitor MG132 stabilizes the level of the Pol(T304I) protein (right panel).
The immunoblot from two independent experiments are shown in Supplementary Figure S1I. Bottom panels: The relative level of Pol and of PCNA was
determined by densitometry and was quantified using Image Lab (Bio-Rad) and the ratio of band densitometry of Pol/PCNA is shown. The ratios for
each cell line at time 0 were normalized to 1 (25 g ofWCLwas loaded per lane). Plots show the mean± SD of three independent experiments. The relative
level of Pol(WT) was compared to Pol(T304I) in HCT116 cells treated with Cyc (P< 0.001) or Cyc+MG132; (P> 0.05), as determined by regular two-
way ANOVA. (E) Pol(T304I) mutation promotes enhanced ubiquitylation of Pol in HCT116 cells. HCT116 cells expressing EGFP, Flag-Pol(WT) or
Flag-Pol(T304I) were transiently transfected with pcDNA-HA-ubiquitin and the Flag-tagged proteins were immunoprecipitates with Flag-M2 agarose.
The ubiquitylated form of Pol was examined by immunoblot using an HA antibody, as shown. The relative level of ubiquitylated Pol (WT or T304I)
was determined by densitometry and was quantified using ImageJ and the relative level of ubiquitylated Pol was calculated by determining the ratio of
ubiquitylated Pol/loaded Pol, as shown in the plot to the right (10 l of IP eluates was loaded into each lane). The immunoblot from three additional
independent experiments are shown in Supplementary Figure S1J; P < 0.05, unpaired t-test was used for the statistical analysis.
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Figure 2. Blocking ubiquitylation does not promote the stability of the cancermutant protein Pol(T304I). (A) A scheme depicting the domains of Pol and
the mutations in Pol used in this study. The vectors used express Pol with an N-terminal Flag-tag (DYKDDDDK). The wild-type protein is designated
WT; the focus of this study is the T304I mutant, originally identified in colon cancer (11); the double mutant whereby the lysine residues targeted for
ubiquitylation have been changed to alanine (K206A/K244A) is denoted as DM (18); the triple mutant or separation of function mutant of Pol that
does not bind XRCC1 (L301R/V303R/V306R) is denoted as TM (18). Compound mutants were also developed, as listed in Supplementary Table S2. (B)
Immunoblot showing the basal level of Pol(T304I) expressed in HCT116 cells and with alanine mutations in the ubiquitylation sites K244 and K206.
The double mutation (K206A/K244A) is denoted as DM. The level of PCNA is shown as a loading control. (C) Immunoblot showing the basal level
of Pol(WT) and Pol(T304I) expressed in LN428 cells and Pol(T304I) with alanine mutations in the ubiquitylation sites K244 and K206. The double
mutation (K206A/K244A) is denoted as DM. The level of XRCC1 is also shown, with PCNA as a loading control. (D) Immunoblot showing enhanced
ubiquitylation of Pol(T304I), as compared to Pol(WT), in LN428 cells (top) and HCT116 cells (bottom). Also shown is the reduced ubiquitylation
of Pol(T304I) with alanine mutations in the ubiquitylation sites K244 and K206. The double mutation (K206A/K244A) is denoted as DM. Total Pol
levels in the WCL are evaluated by immunoblot using the anti-Flag (M2) antibody. The level of PCNA in the WCL is shown as a loading control. (E)
Plots denoting the basal level of Pol(WT), Pol(T304I) and Pol(T304I/DM) expressed in LN428 cells in the presence of cycloheximide (Cyc) or Cyc
+ MG132 for the times indicated (the double mutation K206A/K244A is denoted as DM). The images of three independent experiments are shown in
Supplementary Figure S2C. The relative level of Pol treated with Cyc or Cyc +MG132 was determined by densitometry and was quantified using Image
Lab (Bio-Rad) and calculated as the ratio of Pol/PCNA. Results indicate the mean ± SD of three independent experiments.
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or DM mutation blocks ubiquitylation of Pol(T304I). As
expected, since it has reduced binding to XRCC1, the Flag-
Pol(T304I) protein is highly ubiquitylated when expressed
in LN428 or HCT116 cells (Figure 2D). Further, K to A
modification of the ubiquitin target lysine residues 206 and
244 blocks the ubiquitylation of Flag-Pol(T304I) in both
LN428 cells and HCT116 cells (Figure 2D). However, the
basal level of Flag-Pol(T304I) is very low, prompting an
analysis of its stability. A cycloheximide chase assay con-
firms that the DM mutation of the T304I mutant, Flag-
Pol(T304I/DM), does not block the enhanced turnover of
the protein, whileMG132 treatment partially or completely
prevents the degradation of Flag-Pol(T304I) and Flag-
Pol(T304I/DM) when expressed in LN428 or HCT116
cells (Figure 2E and Supplementary Figure S2C and D).
Together, these findings suggest that the enhanced turnover
of Flag-Pol(T304I) in LN428 and HCT116 cells may be
mediated by a ubiquitin-independent proteasomal degrada-
tion pathway.
An interaction with NQO1 regulates the NADH-dependent
and ubiquitin-independent proteasome-mediated degradation
of Pol
The ubiquitin-independent proteasomal degradation path-
way is mediated by the 20S proteasome. There are several
proposed regulatory mechanisms of this pathway, including
disassembly of the proteasome, gene regulation and interac-
tion with regulatory proteins (35). Proteins known to regu-
late the function of the 20S proteasome include the molec-
ular chaperone heat shock protein 90 (HSP90), the DNA
damage signaling protein poly-ADP-ribose polymerase 1
(PARP1) andNAD(P)H quinone dehydrogenase 1 (NQO1)
(35). We have demonstrated that HSP90 does not inter-
act with Pol (18) and although PARP1 binds to XRCC1
(19), we do not find a direct interaction between Pol and
PARP1. Further, we show herein that the T304Imutation of
Pol disrupts the interaction with XRCC1, minimizing the
level of PARP1 among the proteins bound to Pol(T304I)
(Figure 1B and Supplementary Figure S3A). As NQO1 has
been shown to regulate the degradation of p53, ODC, Hif-1
and other proteins mediated by the 20S proteasome (35,53–
55) (Figure 3A), we hypothesized that NQO1 may similarly
regulate the degradation of Pol(T304I).
We find that GST-Pol interacts with endogenous NQO1
(Figure 3B, left panel) when probing cell lysates from
HCT116, LN428 and T98G cells. Conversely, GST-NQO1
binds to endogenous Pol and endogenous Pol binds
to endogenous NQO1, confirming the interaction between
the two proteins (Figure 3B, right panel). This prompted
us to investigate how the Pol(T304I) mutation affects
this interaction. Using GST-Pol and a series of GST-
Pol mutants (Supplementary Table S2), including DM,
T304I, T304I/DM and K72A, we evaluated how these mu-
tations in Pol affect the interaction with NQO1 and the
related 20S proteasome (C2) and 19S proteasome (TBP1)
proteins. Here, we find that GST-Pol(T304I) binds less
NQO1, as compared to GST-Pol(WT), and has a greater
affinity for the 20S proteasome (C2), when probing lysates
of LN428 or T98G cells (Figure 3C and Supplemen-
tary Figure S3A and B). We next purified recombinant
NQO1 and NQO1(Y128F) (Supplementary Figure S3F)
and show, using an in vitro protein binding assay, that GST-
Pol(T304I) binds less NQO1 than does GST-Pol(WT)
or GST-Pol(TM) (Figure 3D). Interestingly, the TM mu-
tant (L301R/V303R/V306R), Pol(TM), also disrupts the
Pol/XRCC1 interaction (18) yet we find that this muta-
tion in Pol does not affect the Pol/NQO1 interaction.
This suggests that the interaction of Pol with NQO1 is not
regulated by the status of the Pol complex with XRCC1
(bound to or free of XRCC1) but instead is impacted by the
presence of the cancer mutation, T304I.
As per current models, the regulation of the 20S protea-
some function by NQO1 is NADH-dependent (53,54,56)
(Figure 3A). We therefore performed pharmacologic and
genetic experiments to address whether NADH mediates
the Pol/NQO1 interaction. Dicumarol (400 M), a com-
pound that specifically blocks NADH binding to NQO1
(57), disrupts the interaction of Pol with NQO1 (Figure
3C) and promotes the degradation of endogenous Pol
and p53 (positive control) in a dose-dependent manner in
HCT116, LN428 and T98G cells (Figure 3E and Supple-
mentary Figure S3D). Further, we found that dicumarol
treatment promotes the degradation of Flag-Pol(WT)
when overexpressed in LN428 and T98G cells (Supple-
mentary Figure S3E). To confirm that the interaction of
Pol with NQO1 stabilizes Pol, we depleted NQO1 in
LN428 cells by shRNA (KD). We found that depletion of
NQO1 in LN428 cells (LN428/NQO1-KD) results in lower
basal levels of Pol (Supplementary Figure S3C). Next,
we tested the interaction of Pol with NQO1(WT) as well
as the mutant protein NQO1(Y128F), containing a muta-
tion in the NADH-binding site (58). Less Pol is bound
to NQO1(Y128F) than to NQO1(WT) in an in vitro GST-
pulldown assay (Figure 3D). Together, these data suggest
that NQO1 mediates ubiquitin-independent degradation of
Pol in an NADH-dependent manner. To further test if
the ubiquitin-independent proteasome degradation of Pol
was regulated by the Pol/NQO1 interaction, we next per-
formed an in vitro degradation assay. Here, we find that
Pol(T304I) is degradedmore effectively than Pol(WT) by
the 20S proteasomewhen evaluated in vitro. In addition, the
proteasome inhibitor MG132 or the addition of NQO1 im-
pedes the degradation of both Pol(T304I) and Pol(WT)
(Figure 3F and Supplementary Figure S3G). The protec-
tion of Pol by its interaction with NQO1/NADH suggests
that NQO1 may play a role as a gatekeeper of the 20S pro-
teasome and that NQO1 may prevent Pol targeted degra-
dation by the 20S proteasome. Overall, this highlights a reg-
ulatory role for NQO1 in the ubiquitin-independent degra-
dation of Pol.
Oxidative stress promotes the dissociation of Pol and
NQO1 and enhances the association of Pol with XRCC1
The proteolytic capacity of the 20S proteasome is elevated
in cells responding to oxidative stress (35,59,60). NQO1, a
known regulator of the 20S proteasome, plays an impor-
tant role in cells exposed to oxidative stress (61,62), and
it has been suggested that the interaction of NQO1 with
target proteins such as p53 and ODC is modulated by ox-
idative stress (53,54). Since we found that Pol interacts
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Figure 3. NADH regulates the binding and interaction of Pol and NQO1. (A) Illustration depicting the interaction of target proteins with NQO1 to
mediate ubiquitin-independent proteasome degradation. (B) Pol interacts with NQO1. (Left panel) The representative immunoblot shows the proteins in
LN428, HCT116 and T98G cell lysates binding to GST-Pol, including NQO1, XRCC1, PARP1 and the 20S and 19S proteins C2 and TBP1, respectively,
as compared to GST alone. (Top right panel) The immunoblot shows that GST-NQO1 and GST-NQO1(Y128F), but not GST-EGFP, bind to Pol in cell
lysates from LN428 cells. (Bottom right panel) The immunoblot shows that endogenous Pol binds to endogenous NQO1 in LN428 and T98G cells. For
all lanes, 10 l of IP eluates were loaded, separated by SDS-PAGE and probed by immunoblot. However, to probe for the level of loading, 0.5 l of the
IP eluate was loaded into each lane and evaluated by IB with the anti-GST Ab. (C) The cancer mutant Pol(T304I) has reduced binding to NQO1 and
dicumarol treatment disrupts the interaction between Pol and NQO1. Glutathione-agarose was mixed with cell lysates prepared from BL21-Codonplus-
RP cells expressing GST-Pol(WT) and its mutants and GST-EGFP to bind the indicated GST-tagged proteins. Glutathione-agarose/GST-Pol(WT)
(or Glutathione-agarose bound to GST-Pol mutants or GST-EGFP, as indicated) was incubated with cell lysates prepared from LN428 cells or cells
treated with 400 M dicumarol for 5 h. Shown is an immunoblot indicating the level of bound NQO1, PARP1, XRCC1, TBP1 or C2. The images of two
additional independent experiments are shown in Supplementary Figure S3A. The level of C2,NQO1 and Pol (anti-GST)was determined by densitometry
and quantified using Image Lab (Bio-Rad). The ratio of C2 to Pol (P< 0.05) and the ratio of NQO1 to Pol (P< 0.001) was calculated and plotted (right
panel); Student’s t-test. (D) Pol interacts withNQO1 in vitro. Glutathione-agarose/GST-Pol(WT) (or Glutathione-agarose bound toGST-Polmutants,
as indicated) was incubated with recombinant, purified NQO1 or NQO1(128F). Shown is an immunoblot indicating the level of bound NQO1; [S] = short
exposure time; [L] = long exposure time. (E) Dicumarol treatment induces the degradation of endogenous Pol and p53 (positive control) in human cells.
The level of Pol, p53, PARP1, XRCC1, NQO1 and PCNA in WCL was determined by immunoblot analysis of cell lysates prepared from control cells
or after treatment with dicumarol; 200 or 400 M, 5 h (the cell lines as indicated). The images of two additional independent experiments are shown in
Supplementary Figure S3C. [S] = short exposure time; [L] = long exposure time. Quantitation summary of all three blots shown on the right. * P < 0.05,
** P< 0.01, **** P< 0.0001, ns: P> 0.05; compared to untreated cells. One-way ANOVA with Dunnett’s multiple comparisons test was used for the plot
shown. (F) NQO1 protects Pol from 20S proteasome in vitro. Purified Pol(WT) or Pol(T304I) (200 ng) was incubated with 20S proteasome alone or in
the presence of DMSO (0.5%),MG132 (50M),NQO1 (500 ng) or NQO1 (500 ng) plus 5mMNADH, at 37◦C for 1 h. Shown is an immunoblot indicating
the level of Pol, NQO1 or 20S proteasome (C2). The images of two additional independent experiments are shown in Supplementary Figure S3G. The
level of Pol was determined by densitometry and was quantified using Image Lab (Bio-Rad). The ratio of Pol(WT) or Pol(T304I) ± the components
listed was calculated and plotted (right panel); * P < 0.05, ** P < 0.01 and ns: P > 0.05. One-way ANOVA with Dunnett’s multiple comparisons test was
used for the plot shown.
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with NQO1, we evaluated how oxidative stress affects the
Pol/NQO1 interaction. We find that exposure of LN428
cells to H2O2 (150 M, up to 3 h) promotes the dissocia-
tion of NQO1 from Pol in a time-dependent manner, re-
sulting in the loss of >50% of the level of Pol bound to
NQO1 (Figure 4A and Supplementary Figure S4A), with
no significant change at increased doses of H2O2 (Figure
4B and Supplementary Figure S4B). Conversely, the abun-
dance of NQO1, Pol and other BER-related proteins re-
main constant (Figure 4A and Supplementary Figure S4A).
Similar results were also seen when evaluating the impact
of H2O2 treatment on the Pol/NQO1 complex in T98G
cells (Supplementary Figure S4C and D). Interestingly, the
level of NQO1 in T98G cells is highly elevated as compared
to LN428 cells (Figure 3E), impacting the oxidative stress-
induced effect on the Pol/NQO1 interaction (Supplemen-
tary Figure S4C and D).
Hydrogen peroxide (H2O2) treatment damagesDNA suf-
ficiently to activate PARP1 to produce poly(ADP-ribose),
resulting in the cellular depletion of NAD+ and ATP
(48,63). Since regulation of the 20S proteasome byNQO1 is
NADH-dependent (53,54,56), we hypothesized that H2O2
treatment may therefore alter the NAD+/NADH ratio to
promote the dissociation of the NQO1/Pol complex. To
that end, we measured the level of NAD+ and NADH in
LN428 cells exposed to H2O2 for 3 h (150, 200 and 250
M). While the treatment significantly decreased the level
of NAD+, there was no significant change in the level of
NADH (Figure 4C), suggesting that it is the level of NAD+
or the NAD+/NADH ratio that may impact the status of
the NQO1/Pol complex.
H2O2 treatment results in the oxidation of many pro-
teins (35), potentially altering protein function or protein
complex formation. The oxidation of XRCC1 enhances
its binding affinity with Pol by forming additional hy-
drophobic interactions (36,64) (Figure 1A), thereby pro-
moting Pol recruitment to sites of DNAdamage (65). This
would suggest that oxidative stress may trigger a switch,
promoting the dissociation of the Pol/NQO1 complex
(Figure 4A and B) and the association of Pol with the
oxidized form of XRCC1. To test this hypothesis, we eval-
uated the level of Pol bound XRCC1 by IP/IB follow-
ing treatment of cells with H2O2 (150 M, 0–3 h). In-line
with the increased binding affinity of oxidized XRCC1 for
Pol (36,64), we find an increase in the Pol/XRCC1 com-
plex in response to H2O2 treatment in LN428 cells (Fig-
ure 4D and Supplementary Figure S4E and F) and T98G
cells (Supplementary Figure S4G). The increase in the level
of the Pol/XRCC1 complex may be a reflection of either
an increase in the level of Pol localized to chromatin or
an increase in Pol expression. Upon H2O2 treatment of
LN428 cells, we find that there is an increased level of Pol
in the chromatin fraction when normalized to the level of
PARP1 at 12 and 24 h post-treatment, whereas there is no
change in the XRCC1/PARP1 ratio (Figure 4E and Supple-
mentary Figure S4H and I). However, we find no change in
the total level of Pol in whole cell lysates (Figure 4F and
Supplementary Figure S4J and K). To confirm this find-
ing, we used immunofluorescence confocal microscopy to
quantify nuclear Pol and evaluate changes in Pol stain-
ing in response to H2O2 (150 M, 24 h). In-line with the
biochemical/immunoblot analyses, we find a significant in-
crease in Pol nuclear staining following H2O2 treatment
(100–200 cells for each condition; ****P < 0.00001 (Sup-
plementary Figure S4L).
The interaction of Pol with XRCC1 promotes chromatin lo-
calization of Pol
The interaction of Pol with XRCC1 plays a key role in re-
cruiting Pol to sites of DNA damage (18,66). As we have
shown, mutations in Pol that block its interaction with
XRCC1 reduce the stability of Pol and diminish its ability
to be recruited to sites of DNA damage (18). Given this role
of XRCC1 in facilitating the recruitment of Pol, it is also
conceivable that the interaction between Pol and XRCC1
may dictate the sub-cellular distribution of Pol. To test
this possibility, we generatedXRCC1 knockout cell lines us-
ing CRISPR/Cas9 technology in LN428, U2OS and T98G
cells. We then isolated protein fractions of the cytosol, nu-
cleoplasm and chromatin from these cell lines. Expression
of Cas9 had no effect on the level or distribution of Pol
or XRCC1 in U2OS (Supplementary Figure S5B), T98G
(Supplementary Figure S5E and F) or LN428 cells (Sup-
plementary Figure S5G). However, loss of XRCC1 caused
a significant alteration of the distribution and levels of Pol
in all three cell lines. Relative levels of Pol in the chromatin
fraction were reduced, while levels of Pol in the cytoplasm
were increased in all three knockout cell lines relative to
their respective parental cells (Figure 5A–C). Overall, lev-
els of Pol were also reduced in all three XRCC1-KO cell
lines relative to parental control cells (Supplementary Fig-
ure S5D–G). These data strongly suggest a role for XRCC1
in the sub-cellular distribution of Pol as well as the overall
level of Pol, the latter in-line with our earlier report and
as reported by others (18,67). To assess whether this is due
to transcriptional regulation or due to the disruption of the
Pol/XRCC1 complex, we expressed the Flag-tagged Pol
mutants that are incapable of interacting with XRCC1 as
well as Flag-Pol(WT) in LN428 cells, then probed the iso-
lated protein fractions, as above. The relative levels of Flag-
Pol(T304I) in the chromatin fraction were significantly
lower than that of Flag-Pol(WT) (Figure 5D and Supple-
mentary Figure S5A), strongly suggesting that Pol’s inter-
actionwithXRCC1 facilitates its chromatin localization. To
further assess the role of XRCC1 in Pol distribution and
levels, we used immunofluorescence to visualize and quan-
tify relative Pol levels in the nucleus and cytosol. In agree-
ment with our biochemical data, we observed a shift from
nuclear to cytoplasmic localization as well as a reduction in
overall levels of Pol inU2OS/XRCC1-KO (Figure 5E) and
T98G/XRCC1-KO (Supplementary Figure S5I) cell lines
relative to parental cells. Together, these data provide strong
evidence that the interaction between Pol and XRCC1 is
required for Pol sub-cellular distribution and stability.
DISCUSSION
DNA repair pathways maintain the integrity of the genome
and thereby help prevent the onset of cancer, disease and
aging phenotypes (68). Consequently, it has been suggested
that all cancer cells are likely defective in some aspect of
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Figure 4. Oxidative stress promotes the dissociation of Pol with NQO1 and enhances the association of Pol with XRCC1. (A) H2O2 treatment of
LN428 cells promotes the dissociation of the Pol/NQO1 complex. The representative immunoblot shows the proteins in LN428 cell lysates bound to
GST-NQO1, including Pol, PARP1 and XRCC1, respectively, and the variation of the bound proteins upon treatment of LN428 cells with H2O2 (150
M, 0–3 h). The images of two other independent experiments are shown in Supplementary Figure S4A. The level of Pol and of NQO1 was determined
by densitometry and was quantified using Image Lab (Bio-Rad). The ratio of Pol/NQO1 was calculated and plotted (right panel); * P < 0.05, *** P <
0.001, compared to time = 0. One-way ANOVA with Dunnett’s multiple comparisons test was used for the plot shown. (B) H2O2 treatment of LN428
cells (dose response) promotes the dissociation of the Pol/NQO1 complex. The images of four independent immunoblot analyses (Supplementary Figure
S4B) show the proteins in LN428 cell lysates bound to GST-NQO1, including Pol, PARP1 and XRCC1, respectively, and the variation of the bound
proteins upon treatment of LN428 cells with H2O2 (0–250 M, 3 h). The level of Pol and NQO1 was determined by densitometry and was quantified
using Image Lab (Bio-Rad) and the ratio of Pol/NQO1 was calculated and plotted; ** P < 0.01, comparison to cells without H2O2 treatment. One-way
ANOVAwith Dunnett’s multiple comparisons test was used for the plot shown. (C) Plot (top) shows the relative level of NAD+ and NADH in LN428 cells
following treatment with H2O2 (0, 150, 200 and 250 M, 3 h); *** P< 0.0005, compared to untreated cells; **** P< 0.0001, compared to untreated cells.
Plot (bottom) indicates the ratio of NAD+ to NADH calculated from the plot above. One-way ANOVA with Dunnett’s multiple comparisons test was
used for both plots. (D) H2O2 treatment promotes the association of Pol with XRCC1 in LN428 cells. The representative immunoblot (top panel) shows
the proteins immunoprecipitated using an Ab to Pol (monoclonal Ab, clone 61). Proteins were analyzed from control LN428 cells or those treated with
H2O2 (150 M, 0.5–3 h). The immunoprecipitated proteins were probed by immunoblot for the level of Pol and XRCC1. The images of two additional
independent experiments are shown in Supplementary Figure S4E. The ratio of XRCC1/Pol was quantified and plotted; * P < 0.05, compared to time
= 0. One-way ANOVA with Dunnett’s multiple comparisons test was used for the plot shown. (E) Oxidative stress promotes nuclear translocation of Pol
but not XRCC1 in LN428 cells. The sub-cellular distribution of Pol in LN428 cells, either control cells or those treated with H2O2 (150 M, 0–24 h),
was evaluated by immunoblot. Proteins of the cytosol and chromatin fractions from LN428 cells were isolated (10 l of cytosol and chromatin fractions
were loaded and the level of Pol, PARP1, XRCC1 and -tubulin was examined by immunoblot). The images of three independent experiments are shown
in Supplementary Figure S4H. The levels of Pol, XRCC1 and PARP1 in the chromatin fraction were determined by densitometry and quantified using
Image Lab (Bio-Rad). The ratio of Pol/PARP1 and XRCC1/PARP1 was calculated and plotted; ** P < 0.01, compared to time = 0. One-way ANOVA
with Dunnett’s multiple comparisons test was used for the plot shown. (F) Oxidative stress does not alter the basal expression level of Pol in LN428 cells.
The level of Pol in WCL in LN428 cells, either control cells or those treated with H2O2 (150 M, 0–24 h), was evaluated by immunoblot (25 g of WCL
were loaded and the level of Pol, PARP1, XRCC1 and -tubulin was examined by immunoblot). The images of three independent experiments are shown
in Supplementary Figure S4J. The levels of Pol and -tubulin were quantified using the Image Lab software (Bio-Rad), and the ratio of Pol/-tubulin
was determined by densitometry and quantified using Image Lab (Right Panel). ns: P > 0.05, one-way ANOVA with Dunnett’s multiple comparisons test
was used for the plot shown.
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Figure 5. Pol/XRCC1 interaction promotes nuclear and chromatin localization of Pol. (A–C) CRISPR/Cas9-mediated knockout of XRCC1 reduces
chromatin localization of Pol. Cells were fractionated into cytoplasmic (Cy), nucleoplasmic (Nu) and chromatin (Ch) fractions and probed by im-
munoblot. Levels of Pol in each fraction were determined by densitometry and quantified using Image Lab. Relative distribution of Pol between Cy, Nu
and Ch fractions was measured and compared by one-way ANOVA followed by Dunnett’s multiple comparison test. Reduced chromatin localization was
observed in LN428 (Panel A, Supplementary Figure S5G), U2OS (Panel B, Supplementary Figure S5D) and T98G (Panel C, Supplementary Figure S5F)
cell lines; * P < 0.05, ** P < 0.01. (D) Pol mutant incapable of binding to XRCC1 exhibits reduced chromatin localization. Flag-Pol(WT) and Flag-
Pol(T304I) were expressed in U2OS cells and levels of Pol in each fraction from four immunoblots (Supplementary Figure S5A) were measured. Pol
levels are expressed as ratios relative to cytoplasmic Pol levels for nucleoplasmic (Nu/Cy) and chromatin (Ch/Cy) fractions, and ratios were compared
by Student’s t-test; * P < 0.05. (E) The sub-cellular distribution of Pol and XRCC1 in U2OS cells was also evaluated by immunofluorescence. Pol and
XRCC1 were probed with anti-Pol and anti-XRCC1 antibodies, and the nuclear and cytoplasmic compartments were defined by staining with DAPI and
phalloidin conjugated to AlexFluor 647, respectively. Top panel: Images were collected (scale bar = 10 m) and staining intensity was quantified using a
custom analysis macro written for NIS-Elements. Bottom panels: Quantified data were compared using one-way ANOVA followed by Tukey’s multiple
comparison test. U2OS cells in which XRCC1 was knocked out show a reduction in both overall levels of Pol (left) and nuclear/cytoplasmic ratios of
Pol (right); **** P < 0.0001.
DNA repair (69,70). Protein–protein interactions are essen-
tial for most cellular functions, including but not limited to
replication, transcription, mitochondrial function, apopto-
sis and DNA repair (19,71–74). The BER pathway can be
represented as a series of coordinated and sequential DNA
repair protein complexes. These repair complexes rely on
critical protein–protein interactions to promote assembly
in response to post-translational protein modifications to
facilitate repair (19). As such, mutations in critical protein
complex interfaces could disrupt and inhibit DNA repair.
One of the central and critical protein sub-complexes
in BER is the heterodimer of DNA polymerase  (Pol)
and XRCC1. Pol and XRCC1 form a tight complex via
an interaction between the C-terminal domain of Pol
and the N-terminal domain of XRCC1 (21,36,37). As we
have reported, the Pol/XRCC1 heterodimer plays an im-
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Figure 6. Oxidative stress-induced regulation of Pol protein sub-cellular localization. Proposed model highlighting the regulation of Pol protein sub-
cellular localization by oxidative stress. The Pol/NQO1 interaction regulates the level of Pol in the cytosol by preventing the ubiquitin-independent
proteasome pathway. Conversely, the Pol/XRCC1 interaction regulates the level of Pol in the nucleus by preventing activation of the ubiquitin-dependent
proteasome pathway. Oxidative stress promotes the regulation of the binding partners, alternating from Pol bound to NQO1 ⇒ Pol bound to XRCC1,
promoting the chromatin localization of Pol.
portant role in regulating the ubiquitylation and degrada-
tion of Pol (18). A TCGA analysis of the majority of
the BER genes reveals they are altered in 3977 (9%) of
44648 sequenced cases/patients (46 139 total) (75,76). Mis-
sense, frame shift and truncating mutations for Pol and
XRCC1 are uniformly found across the gene for each (Sup-
plementary Figure S6). Interestingly, among the Pan Can-
cer TCGA samples, only three missense mutations were
found inXRCC1within the Pol-interaction domain (span-
ning residues 67–86; A79T, E81D and E85K), while no mis-
sense mutations were identified in Pol within the XRCC1-
interaction domain (spanning residues 301–309). A more
detailed analysis ofmutations thatmay impact protein com-
plex formation has yet to be accomplished.
Of the many mutations recently identified in a large co-
hort of colon cancer patients, as many as 75% of the tu-
mors presented with POLB gene mutations (11). One of
these colon cancer mutations is located within the XRCC1-
interacting domain or V303 loop, the T304I mutation (11).
In our investigation of the cellular impact of the T304I can-
cer mutation of DNA Polymerase  (Pol), we find that
mutation of this surface threonine residue impacts critical
and novel Pol protein–protein interactions. In-line with
our earlier report (18), the T304I mutation, found within
the V303 loop, significantly impacts the ability of Pol
to interact with XRCC1. As we show herein, we observe
reduced interaction between Pol(T304I) and XRCC1 in
cell lysates and a significant decrease in binding affinity
when evaluating purified proteins (the binding affinity of
Pol(WT) to XRCC1 is 2.38- to 12.48-fold higher than
that of Pol(T304I)). Also predicted from our previous re-
port (18) is the instability of the Pol(T304I) protein that
is triggered by the reduced binding affinity for XRCC1. In
addition, the reduced interaction of the Pol(T304I) mu-
tant protein with XRCC1 revealed a novel Pol interac-
tion partner protein, NAD(P)H quinone dehydrogenase 1
(NQO1), a known regulator of the 20S proteasome. Overall,
we find that the proteasome-mediated degradation of Pol
is regulated by both ubiquitin-dependent and ubiquitin-
independent processes.
The present study highlights a novel mechanism of a
ubiquitin-independent proteasome pathway regulating the
level of Pol, whereby NQO1 interacts with and stabi-
lizes Pol by preventing its degradation in the cytosol. We
demonstrate here that modification of the bona fide Pol
ubiquitylation site residues K206 and K244 (18) completely
blocks the ubiquitylation of Pol(T304I) yet fails to stabi-
lize the Pol(T304I) protein and in fact promotes its degra-
dation. Together, we find that the ubiquitin-independent
proteasome pathway regulates the stability of Pol in the
cytosol, via an interaction between Pol and NQO1 in an
NADH-dependent manner. Conversely, the interaction of
Pol with XRCC1 plays a key role regulating the stability
of Pol via a ubiquitin-dependent pathway.
The 20S proteasome preferentially degrades oxidized
proteins (35,77) and in many cases, the capacity of the 20S
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proteasome is elevated in cells responding to oxidative stress
(35,59,60). Proteins known to regulate the function of the
20S proteasome include NQO1 (35). Oxidative stress pro-
motes the association of NQO1 with p53 yet mediates the
dissociation of NQO1 fromODC (53,54). Given the critical
role for the BER pathway in the cellular response to oxida-
tive stress-induced DNA damage, it is interesting that we
find these two pathways converge. Here, we show that ox-
idative stress promotes the dissociation of the Pol/NQO1
complex, enhancing the interaction of Pol with XRCC1.
Interestingly, the basal level of Pol, XRCC1 and NQO1
proteins do not change in response to oxidative stress, sug-
gesting that the interaction of Polwith XRCC1 plays a key
role in stabilizing Pol when dissociated from NQO1. Ox-
idative stress impacted the level of NAD+ rapidly and had
a minor impact (if any) on the level of cellular NADH. Al-
though we observe only a minimal change in NADH, the
overall NAD+/NADH ratio is reduced. This is similar to
what we have found for treatment of cells with alkylating
agents, activating a strong PARP1 response, a reduction in
NAD+ yet no measurable reduction in NADH (48). It is
likely that the local concentration of NADH (cytosolic) is
altered to a greater extent, promoting the dissociation of
Pol from NQO1. However, it should be noted that the ra-
tio of free NADH/NAD+ is∼0.0001 in the cytosol, while it
is∼0.143 in themitochondria (78). As such, the bound frac-
tion of NADH dominates the measurement (79), thereby
limiting the measurable change in free NADH upon oxida-
tive stress, especially within a few hours of exposure. This
would be consistent with known sub-cellular changes in
NAD+ and NAD-metabolites in response to cellular stress
(48,80).
Efficient BER requires localization of Pol in the nucleus
and, more specifically, in the chromatin fraction so as to be
available for repair of base damage (81). As with many pro-
teins, Pol contains a nuclear localization sequence, located
at its N-terminus, contributing to the transport of Pol to
the nucleus (82). Herein, we find that XRCC1 also influ-
ences the nuclear localization of Pol, potentially impacting
the capacity of Pol for recruitment to sites of DNA dam-
age. In the absence of XRCC1, Pol protein is reduced in
both the nuclear and chromatin protein fraction and by im-
munofluorescence confocal microscopy, we find a reduction
in the total level of Pol and a reduction in the nuclear-to-
cytosolic ratio of Pol.
In this study, we have characterized the colon cancer mu-
tant of Pol, T304I. Our analysis has revealed a new model
that may govern Pol protein stability and sub-cellular lo-
calization (Figure 6). Specifically, we find that the degra-
dation of Pol is regulated by both ubiquitin-dependent
and ubiquitin-independent proteasome processes. In this
context, Pol forms two unique protein complexes. The
interaction with NQO1 regulates the stability of Pol in
the cytosol. Given the recent discovery that Pol plays
a role in mitochondrial BER by us and others (83,84),
maintaining the cytosolic stability of Pol may be impor-
tant for mitochondrial genome maintenance. Conversely,
we find that oxidative stress promotes the dissociation of the
Pol/NQO1 complex, enhancing the interaction of Pol
with XRCC1. The interaction with XRCC1 then regulates
the stability of Pol via a ubiquitin-dependent pathway.
Further, we find that XRCC1 plays a key role in the sub-
cellular localization of Pol that is expected to impact the
ability of Pol to be recruited to sites of DNA damage.
Overall, our results reveal that somatic mutations that mit-
igate protein–protein interactions or disrupt key protein
complexes can impact protein function by regulating pro-
tein stability and sub-cellular localization.
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